Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Esophagogastric Cancer 1Breast Cancer Metastases 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × zirconium-89-trastuzumab × Clear all
NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡